Three independent discounted-cash-flow-style models value United Therapeutics Corporation every trading day. 2 of 3 currently price UTHR above its market price.
| Free Cash Flow model | $898.73 |
| Excess Profit model | $815.64 |
| Residual Earnings model | $237.70 |
| Dividend Discount model | — |
| Piotroski F-Score | 7 / 9 |
| Return on invested capital | +16.9% |
| Net debt / EBITDA | -1.0× |
| Gross margin | +87.9% |
| Revenue CAGR | +18.0% |
| Cash conversion | 1.2× |
| Dividend yield | — |
| Buyback yield | +2.7% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open UTHR in StockKitty